Skip to content

Diaphragm Structure and Pathobiology in Patients Being Bridged to Lung Transplant

Diaphragm Structure and Pathobiology in Patients Being Bridged to Lung Transplant

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03667027
Acronym
DIASPORA
Enrollment
40
Registered
2018-09-12
Start date
2019-04-01
Completion date
2025-12-30
Last updated
2024-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaphragm Injury, Mechanical Ventilation Complication, Respiratory Failure

Keywords

Diaphragm Dysfunction, Acute Respiratory Failure, Mechanical Ventilation

Brief summary

This study is designed to characterize the changes in diaphragm structure, function and biology during bridging to lung transplant by mechanical ventilation or extracorporeal life support.

Detailed description

Mechanical ventilation has been linked to diaphragm injury and dysfunction. During mechanical ventilation, the amount of breathing work done by the diaphragm is unpredictable: the diaphragm could be completely rested, or it could be overworked. Either of these possibilities may cause injury to the diaphragm. Patients with an injured and dysfunctional diaphragm have greater difficulty weaning from mechanical ventilation - they become too weak to breathe. However, little is known about the relationship between changes in the diaphragm and the histological (structure of cells and tissue) basis of these changes. The investigators have developed a new technique employing beside ultrasound to measure diaphragm thickness. This allows them to observe changes in diaphragm muscle structure and function. The goal of the study is to determine whether different forms of respiratory support (mechanical ventilation vs extracorporeal life support) lead to different degrees of diaphragm injury and to compare changes in the diaphragm seen on ultrasound to changes in the diaphragm tissues under a microscope. This will help the investigators to confirm the best way to avoid diaphragm injury and to understanding the meaning of diaphragm ultrasound images.

Interventions

Mechanical ventilation or extracorporeal life support

Sponsors

The Hospital for Sick Children
CollaboratorOTHER
University Health Network, Toronto
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

(Cases): * Receiving a respiratory support modality as a bridge to lung transplantation * Formally listed for transplantation Inclusion Criteria (Control Group 1): \- Undergoing lung transplantation for either obstructive or restrictive lung disease Inclusion Criteria (Control Group 2): \- Undergoing elective thoracic surgery without any prior history of chronic pulmonary parenchymal disease

Exclusion criteria

(Cases and Controls): * Previously diagnosed with neuromuscular disorder * Received invasive mechanical ventilation for \>48 hours in the preceding four weeks * Thoracic cage deformity

Design outcomes

Primary

MeasureTime frameDescription
Difference in diaphragm thickness and thickening fraction in patients using MV and patients using ECLSChange from baseline diaphragm thickness and thickening fraction at 7 days after lung transplantDiaphragm thickness and injury score will be tested for an interaction between the bridging modality (MV vs. ECLS) and the duration of exposure to the modality on the degree of diaphragm injury and atrophy

Secondary

MeasureTime frameDescription
Correlate changes in diaphragm thickness and histological features of diaphragm dysfunctionAssessed immediately after transplantationHistological features to be assessed are: myofibril cross-sectional area, muscle fiber type, presence of cellular infiltrates, myofiber necrosis and regeneration, autophagy and fibro-fatty infiltration
Biomarkers for diaphragm dysfunctionAssessed immediately before transplantationBiomarkers to be assessed are: skeletal troponin-I and markers of systemic inflammation (IL-1, IL-6, Tumor Necrosis Factor (TNF)-alpha)

Countries

Canada

Contacts

Primary ContactRongyu (Cindy) Jin
rongyu.jin@uhn.ca416-340-4800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026